Washington, DC (PRWEB) April 23, 2011
VaxNet, a network of independently owned, geographically diverse research sites that specialize in multi-therapeutic vaccine trials has won the inaugural Best Clinical Trial Site Network award at the 2011 Vaccine Industry Excellence awards. The awards ceremony, held during the Annual World Vaccine Congress, recognized Benchmark Research, Meridian Clinical Research and Regional Clinical Research – collectively VaxNet, for outstanding performance and management of industry sponsored vaccine trials.
“VaxNet’s sole focus is to rapidly and effectively complete trials for our clients, while providing the cleanest data” stated Debra Gabrielson, CEO of Regional Clinical Research. The “Best Site Network” is the newest category at the ViE Awards and the inclusion of research sites is significant, as the role of the site is not often factored into the role of drug development. Mark Lacy, CEO of Benchmark Research comments, “To be the inaugural Best Site Network is quite an honor for VaxNet. We have committed substantial time and resources in developing our specialty as industry-leading vaccine sites, and being recognized with the ViE award is a culmination of those efforts.”
VaxNet’s clients value the geographic distribution and demographic diversity of the sites within the network, covering Upstate New York, Nebraska, South Dakota, Texas, Louisiana and California. With more than 200 successfully completed trials that have enrolled nearly 20,000 study participants, VaxNet offers immediate access to sites that can effectively meet and exceed your enrollment goals without sacrificing quality. “VaxNet’s consistent, long-standing track record of performance and rapport with our clients is what we feel sets us apart from our competition” stated Nicole Osborn, Owner of Meridian Clinical Research.
For more information about how VaxNet can help you accomplish your vaccine study goals, please contact:
Director of Research and Development